Myelodysplastic Syndromes
"Myelodysplastic Syndromes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Descriptor ID |
D009190
|
| MeSH Number(s) |
C15.378.190.625
|
| Concept/Terms |
Myelodysplastic Syndromes- Myelodysplastic Syndromes
- Myelodysplastic Syndrome
- Syndrome, Myelodysplastic
- Syndromes, Myelodysplastic
- Dysmyelopoietic Syndromes
- Dysmyelopoietic Syndrome
- Syndrome, Dysmyelopoietic
- Syndromes, Dysmyelopoietic
Hematopoetic Myelodysplasia- Hematopoetic Myelodysplasia
- Hematopoetic Myelodysplasias
- Myelodysplasia, Hematopoetic
- Myelodysplasias, Hematopoetic
|
Below are MeSH descriptors whose meaning is more general than "Myelodysplastic Syndromes".
Below are MeSH descriptors whose meaning is more specific than "Myelodysplastic Syndromes".
This graph shows the total number of publications written about "Myelodysplastic Syndromes" by people in this website by year, and whether "Myelodysplastic Syndromes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 3 | 5 | 8 |
| 1995 | 5 | 1 | 6 |
| 1996 | 7 | 2 | 9 |
| 1997 | 5 | 5 | 10 |
| 1998 | 10 | 2 | 12 |
| 1999 | 6 | 0 | 6 |
| 2000 | 11 | 0 | 11 |
| 2001 | 7 | 2 | 9 |
| 2002 | 18 | 6 | 24 |
| 2003 | 18 | 6 | 24 |
| 2004 | 17 | 6 | 23 |
| 2005 | 14 | 3 | 17 |
| 2006 | 23 | 6 | 29 |
| 2007 | 32 | 7 | 39 |
| 2008 | 30 | 2 | 32 |
| 2009 | 29 | 5 | 34 |
| 2010 | 34 | 5 | 39 |
| 2011 | 49 | 1 | 50 |
| 2012 | 26 | 1 | 27 |
| 2013 | 33 | 5 | 38 |
| 2014 | 48 | 4 | 52 |
| 2015 | 41 | 3 | 44 |
| 2016 | 40 | 4 | 44 |
| 2017 | 37 | 6 | 43 |
| 2018 | 44 | 3 | 47 |
| 2019 | 28 | 3 | 31 |
| 2020 | 37 | 1 | 38 |
| 2021 | 41 | 4 | 45 |
| 2022 | 41 | 1 | 42 |
| 2023 | 34 | 1 | 35 |
| 2024 | 8 | 0 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myelodysplastic Syndromes" by people in Profiles.
-
T-cell dysfunctions in myelodysplastic syndromes. Blood. 2024 Apr 04; 143(14):1329-1343.
-
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax. Clin Cancer Res. 2024 Apr 01; 30(7):1319-1326.
-
Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes. Nat Commun. 2024 Mar 18; 15(1):2428.
-
First-in-human study of JNJ-67571244, a CD33 ? CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. Clin Transl Sci. 2024 Mar; 17(3):e13742.
-
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024 02 13; 8(3):591-602.
-
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol. 2024 Mar; 11(3):e186-e195.
-
Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope. Leuk Res. 2024 02; 137:107441.
-
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024 Jan; 11(1):e15-e26.
-
Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2024 04; 24(4):260-268.e2.
-
Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms. Mod Pathol. 2024 Feb; 37(2):100397.